Resona Asset Management Co. Ltd. Trims Holdings in Illumina, Inc. $ILMN

Resona Asset Management Co. Ltd. reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,677 shares of the life sciences company’s stock after selling 4,272 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Illumina were worth $5,748,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Empowered Funds LLC lifted its stake in Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC bought a new position in Illumina during the second quarter worth $621,000. CW Advisors LLC bought a new position in Illumina during the second quarter worth $275,000. Marshall Wace LLP lifted its stake in Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC lifted its stake in Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ILMN has been the topic of several research analyst reports. Piper Sandler reduced their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Barclays raised their price objective on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Canaccord Genuity Group reduced their price objective on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. UBS Group restated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Finally, Citigroup raised their price objective on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $137.75.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $144.41 on Friday. Illumina, Inc. has a 1-year low of $78.55 and a 1-year high of $155.53. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The business’s fifty day moving average price is $130.45 and its two-hundred day moving average price is $130.91. The firm has a market capitalization of $21.85 billion, a PE ratio of 26.26, a P/E/G ratio of 2.40 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the company earned $0.97 earnings per share. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts expect that Illumina, Inc. will post 5.2 EPS for the current year.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith A. Meister sold 104,393 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $145.34, for a total value of $15,172,478.62. Following the sale, the director directly owned 3,500,048 shares of the company’s stock, valued at $508,696,976.32. This trade represents a 2.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 330,160 shares of company stock worth $48,028,308 over the last ninety days. 2.90% of the stock is owned by corporate insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.